{"schema_version":"secwatch.filing_event.v1","accession":"0001494650-24-000068","form_type":"8-K","ticker":null,"cik":"0001494650","company_name":"OptiNose, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.654441+00:00","generated_at":"2026-06-02T00:43:21.542260+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Optinose Q1 XHANCE revenue $14.9M (+26% YoY); FDA approval for chronic sinusitis; guides FY24 rev $85-95M","bullets":["Q1 net revenue $14.9M (+26% YoY); net loss $14.1M ($0.12/shr) vs $18.8M ($0.17) prior year.","FDA approved XHANCE for chronic rhinosinusitis without nasal polyps on Mar 15, 2024 (first Rx treatment).","FY24 guidance: XHANCE net rev $85-95M; avg rev per Rx >$230 (prev ~$220); GAAP op ex $95-101M.","Expects positive GAAP income from operations for full year 2025.","Completed $55M registered direct offering May 10; pro forma cash ~$100M sufficient through 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001494650-24-000068","json":"https://secwatch.observer/filing/0001494650-24-000068.json","markdown":"https://secwatch.observer/filing/0001494650-24-000068.md","text":"https://secwatch.observer/filing/0001494650-24-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/0001494650-24-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/optn-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:43:21.542260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5de349c207d9900c7300d9991a13b0a24b49af97","claim":"OptiNose, Inc. reported quarter ended March 31, 2024 results: revenue $14.9 million, net income $14.1 million, EPS $0.12 per share. Guidance raised.","evidence_excerpt":"First Quarter 2024 Financial Results Total revenues The Company reported $14.9 million in net revenue from sales of XHANCE during the three-month period ended March 31, 2024, an increase of 26% compared to $11.8 million during the three-month period ended March 31, 2023. Costs and expenses and net loss For the three-month period ended March 31, 2024, research and development expenses were $1.2 million and selling, general and administrative expenses were $20.5 million. The net loss for the period was $14.1 million, or $0.12 per share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/0001494650-24-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.9 million"},{"label":"Net income","value":"$14.1 million"},{"label":"EPS","value":"$0.12 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}